We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$127M
Cap. Flow %
-2.7%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Miscellaneous 1.94%
3 Industrials 1.1%
4 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
51
Prelude Therapeutics
PRLD
$361M
$33.7M 0.72%
10,909,256
– –
JANX icon
52
Janux Therapeutics
JANX
$1.01B
$33.4M 0.71%
3,317,927
+481,541
+17% +$5.55M
XENE icon
53
Xenon Pharmaceuticals
XENE
$5.45B
$32.8M 0.7%
958,793
-137,207
-13% -$5.13M
ICLR icon
54
Icon
ICLR
$13.3B
$32.6M 0.69%
+132,200
New +$33.3M
HZNP
55
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$30.8M 0.65%
266,400
-50,000
-16% -$5.37M
APGE
56
DELISTED
Apogee Therapeutics
APGE
$30.4M 0.65%
+1,427,901
New +$31.5M
GRCL
57
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$26.8M 0.57%
9,308,726
+275,000
+3% +$1.01M
TELA icon
58
TELA Bio
TELA
$48.9M
$22.7M 0.48%
2,835,542
– –
IOVA icon
59
Iovance Biotherapeutics
IOVA
$4.24B
$21.4M 0.46%
4,707,458
– –
NMRA icon
60
Neumora Therapeutics
NMRA
$156M
$21.2M 0.45%
+1,500,000
New +$18.7M
VERA icon
61
Vera Therapeutics
VERA
$2.43B
$20.8M 0.44%
1,518,115
-238,685
-14% -$4.1M
RAPT
62
DELISTED
RAPT Therapeutics
RAPT
$20.7M 0.44%
155,618
-766
-0.5% -$125K
ABCL icon
63
AbCellera Biologics
ABCL
$3.7B
$19.2M 0.41%
4,180,768
– –
SNDX icon
64
Syndax Pharmaceuticals
SNDX
$1.62B
$18.6M 0.4%
1,284,000
-1,246,240
-49% -$23.6M
AKRO
65
DELISTED
Akero Therapeutics
AKRO
$17.7M 0.38%
350,000
+150,500
+75% +$7.01M
AZN icon
66
CALL
AstraZeneca
AZN
$251B
$16.9M 0.36%
+125,000
New +$17.1M
ARGX icon
67
argenx
ARGX
$61.3B
$16M 0.34%
32,600
– –
SRRK icon
68
Scholar Rock
SRRK
$6.09B
$14.4M 0.31%
2,033,789
+1,298,144
+176% +$8.72M
QURE icon
69
uniQure
QURE
$2.99B
$13.9M 0.29%
2,064,455
– –
IMA
70
ImageneBio Inc
IMA
$55.8M
$13.8M 0.29%
265,514
– –
ALXO icon
71
ALX Oncology
ALXO
$261M
$13.8M 0.29%
2,871,000
– –
RYTM icon
72
Rhythm Pharmaceuticals
RYTM
$6.66B
$13.4M 0.28%
+583,642
New +$13.1M
VSTM icon
73
Verastem
VSTM
$665M
$12.4M 0.26%
1,529,115
– –
TSBX
74
DELISTED
Turnstone Biologics
TSBX
$12.2M 0.26%
+3,099,265
New +$27.6M
IMTX icon
75
Immatics
IMTX
$1.31B
$12.2M 0.26%
1,050,200
+83,371
+9% +$995K
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.